Business Wire

REMARKABLE

Share
Introducing the World’s Thinnest Tablet, reMarkable 2

reMarkable today announced its next-generation paper tablet, reMarkable 2. The breakthrough device for note-taking and reviewing documents without distractions comes from the Norwegian developers behind the original paper tablet, which broke pre-order records during its 2017 launch.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005154/en/

reMarkable 2 is available for pre-order from reMarkable.com for €399, and is set to ship in June 2020. The limited-time launch offer will include a Marker and Folio.

At 0.19 in/4.7 mm thick, reMarkable 2 is the world’s thinnest tablet. Armed with weeks of battery life, and the breakthrough second-generation CANVAS display partially powered by E Ink technology, reMarkable 2 is the most paper-like digital device the industry has ever seen.

“reMarkable 2 supports our design philosophy of helping people think better through powerful technology,” said Magnus Wanberg, CEO of reMarkable. “Our latest tablet is paper-thin and our innovations in display technology make it so much like writing on paper that it’s hard to tell the difference.”

Inspired by paper, reMarkable 2 is a tool for note-taking, reading, and annotating documents without built-in distractions. “Today’s world is a frenzied place of ever-evolving technology that increasingly demands more of our time and attention. reMarkable 2 is a step in a more human-friendly direction. It’s designed to help people think,” said Wanberg.

The company has spent the last six years developing and perfecting its breakthrough paper tablet to deliver a realistic paper experience that supports improved focus and better thinking, while still maintaining a connection to the digital world.

reMarkable 2 features the ability to convert handwritten notes into text, along with options for organizing, sharing, annotating and searching documents. Among a host of other digital features, reMarkable’s cloud service makes content accessible through multi-platform companion apps for desktop and mobile. Its feature set is aimed at anyone who likes writing by hand, but wants to be able to reuse their work in their digital workflow.

At launch, reMarkable 2 will be accompanied by a Google Chrome plug-in that will allow users to read clean, reformatted web articles on their paper tablet without distractions.

Innovations in ultra-thin, high-friction surface materials and a completely redesigned, second-generation CANVAS display, make reMarkable 2 an unprecedented digital paper device. Millions of physical ink particles lift to the display’s surface, working in tandem with the high precision Marker to deliver exceptional paper-like accuracy.

A range of accessories to compliment reMarkable 2

All accessories are either included in their respective launch bundles, available as a bundle upgrade, or can be purchased separately later in the year when the pre-order finishes.

Markers: reMarkable 2 will launch with two different Markers, both of which attach magnetically to the right side of the paper tablet:
Marker - €59 (included in pre-order)
Marker Plus (includes built-in eraser in the top end) - €99

Folios : Folio and Book Folio have been created with function and style in mind. They’re both made from fine materials and designed to fit reMarkable 2 perfectly.
Folio - €79 - The original sleeve for reMarkable 2 (included in the first part of pre-order)
Book Folio - from €99 - Lets you keep your reMarkable 2 in its cover while working. Attaches magnetically to reMarkable 2

About reMarkable

Based in Oslo, Norway, reMarkable is the leading innovator within the paper tablet category, developing breakthrough digital paper tablets for note-taking, reading, and reviewing documents. Its vision is to create human-friendly products to help people think better. For more information about reMarkable and its digital paper tablet, visit https://remarkable.com

YouTube: https://youtu.be/0dgXuStEm4U
Instagram: https://www.instagram.com/remarkable/
Facebook: https://www.facebook.com/remarkableAS
Twitter: https://twitter.com/remarkablepaper
#remarkablepaper

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye